High-dose nitric oxide as a potential new therapeutic agent against Mycobacterium abscessus.
A. Ghaffari (Harrison, NY, United States of America), J. Da Silva (Bethesda, MD, United States of America), K. Bogdanovski (Bethesda, MD, United States of America), A. Zelazny (Bethesda, MD, United States of America), K. Olivier (Bethesda, MD, United States of America)
Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies
Disease area: Respiratory infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Ghaffari (Harrison, NY, United States of America), J. Da Silva (Bethesda, MD, United States of America), K. Bogdanovski (Bethesda, MD, United States of America), A. Zelazny (Bethesda, MD, United States of America), K. Olivier (Bethesda, MD, United States of America). High-dose nitric oxide as a potential new therapeutic agent against Mycobacterium abscessus.. 5463
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections Source: Eur Respir J, 49 (5) 1700083; 10.1183/13993003.00083-2017 Year: 2017
Nitric oxide - a marker of tuberculosis process activity Source: International Congress 2017 – TB: diagnosis, severity and practical management Year: 2017
Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare? Source: Eur Respir J 2016; 48: 1803-1804 Year: 2016
Cytokine regulation in multidrug-resistant tuberculosis Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers Year: 2016
Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis Source: Eur Respir J 2003; 21: 483-488 Year: 2003
Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021 Year: 2022
Potential for personalised application of inhaled nitric oxide in Covid-19 pneumonia Source: Virtual Congress 2021 – Respiratory failure in COVID19 and beyond Year: 2021
Measurement of exhaled nitric oxide in patients with pulmonary tuberculosis Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013
Nitric oxide gas: a potential respiratory antiviral Source: Eur Respir J 2005; 26: Suppl. 49, 248s Year: 2005
Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients Source: Eur Respir J 2013; 41: 1101-1106 Year: 2013
Nitric oxide in the COPD pathogenesis in patients with pulmonary tuberculosis Source: International Congress 2019 – Oxidative stress, hypoxia and microbial exposure in the pathogenesis of pulmonary disease Year: 2019
Importance of identifying Mycobacterium bovis as a causative agent of human tuberculosis Source: Eur Respir J 2010; 35: 692-694 Year: 2010
Detection of Mycobacterium tuberculosis in children during complex antimycobacterial therapy Source: Annual Congress 2009 - Genetics of lung diseases Year: 2009
Nitric oxide, TNF-α and IFN-γ receptor in MDR-TB patients: a follow-up study Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007
Level of nitric oxide stable metabolites in blood serum of patients with MDR tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 662s Year: 2007
Nitrate⁄nitrite and peroxynitrite in sarcoidosis, related to mycobacteria's stationary-phase Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013
The nitric oxide (NO) metabolites in monitoring and therapy of bronchial asthma Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers Year: 2011
Exhaled nitric oxide measurement in the diagnosis and management of pulmonary tuberculosis Source: Annual Congress 2009 - From bench to bedside: diagnosis of tuberculosis Year: 2009
Exhaled NO levels – A new tool in decision-making about antibiotic treatment Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases Year: 2013
Nitric oxide attenuates the Th1 cells that are upregulated in patients with active pulmonary tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 466s Year: 2001